New

Sativex (Nabiximols)

£50.00

Sativex (nabiximols) is a cannabis-based medicine containing Tetranabinex® and Nabidiolex® extracts of chemically and genetically characterized Cannabis sativa L. plants. The principal active components are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Sativex spray can be used in addition to a person’s current anti-spasticity medication.

Prior to gaining a licence for use in MS-related spasticity, Sativex had been studied for its effects on a number of MS related symptoms including: spasticity and spasms, pain, bladder symptoms, tremor, and sleep disturbance.

Sativex Oromucosal Spray is indicated as an adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. This authorization reflects the promising nature of the clinical evidence of efficacy and safety which must be verified with further studies. Products approved under Health Canada ‘s NOC/c policy, have demonstrated promising benefit, are of high quality and possess an acceptable safety profile based on a benefit/risk assessment for the approved use.

What is SATIVEX used for?
This current conditional approval for SATIVEX is for adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain.
Previous conditional approval for SATIVEX is for the adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis in adults.

How does SATIVEX work?
SATIVEX is thought to act via cannabinoid receptors that are distributed throughout the central nervous system and in immune cells. SATIVEX contains Tetranabinex® and Nabidiolex®, extracts of chemically and genetically characterized Cannabis sativa L. plants (hemp plants). The exact mechanism of action in relieving neuropathic pain or cancer pain is not known.